uniQure (QURE) Cash from Financing Activities (2016 - 2026)
uniQure (QURE) recorded quarterly Cash from Financing Activities of $550000.0 in Q1 2026, down 77.54% quarter-over-quarter from $2.4 million in Q4 2025, and down 99.32% on a YoY basis from $80.7 million in Q1 2025.
uniQure (QURE) Cash from Financing Activities (2016 - 2026) Analysis & Trends
uniQure's Cash from Financing Activities history runs 11 years deep, the most recent figure standing at $550000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 99.32% year-over-year to $550000.0; the TTM figure through Mar 2026 stood at $335.3 million (up 1482.99% YoY), while the FY2025 annual figure was $415.4 million, up 798.31% from the prior year.
- Cash from Financing Activities was $550000.0 for Q1 2026 at uniQure, down from $2.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $370.1 million in Q2 2023 to a low of -$53.0 million in Q3 2024.
- Historically, Cash from Financing Activities has averaged $48.0 million across 5 years, with a median of $301000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 638067.24% in 2023, then sank 14267.39% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $601000.0 in 2022, then plunged by 92.35% to $46000.0 in 2023, then tumbled by 14267.39% to -$6.5 million in 2024, then surged by 137.58% to $2.4 million in 2025, then plunged by 77.54% to $550000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $550000.0 (Q1 2026), $2.4 million (Q4 2025), and $332.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | uniQure | 2.88 Bn | 2.88 Bn | 3.34 Mn | 550,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 550,000.00 |
| Mar 31, 2026 | 550,000.00 |
| Dec 31, 2025 | 2.45 Mn |
| Dec 31, 2025 | 2.45 Mn |
| Sep 30, 2025 | 332.24 Mn |
| Sep 30, 2025 | 332.24 Mn |
| Jun 30, 2025 | 44,000.00 |
| Jun 30, 2025 | 44,000.00 |
| Mar 31, 2025 | 80.67 Mn |
| Mar 31, 2025 | 80.67 Mn |
| Dec 31, 2024 | -6.52 Mn |
| Dec 31, 2024 | -6.52 Mn |
| Sep 30, 2024 | -53.02 Mn |
| Sep 30, 2024 | -53.02 Mn |
| Dec 31, 2023 | 46,000.00 |
| Dec 31, 2023 | 46,000.00 |
| Sep 30, 2023 | -7.59 Mn |
| Sep 30, 2023 | -7.59 Mn |
| Jun 30, 2023 | 370.14 Mn |
| Jun 30, 2023 | 370.14 Mn |